NDC-11 (Package) (Descending) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
55111-0687-25 | 55111-0687 | Gemcitabine | gemcitabine | 1.0 g/25mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | July 25, 2011 | In Use | |
55111-0686-07 | 55111-0686 | Gemcitabine | gemcitabine | 200.0 mg/5mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | July 25, 2011 | In Use | |
55111-0685-07 | 55111-0685 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | March 4, 2013 | In Use | ||
55111-0647-30 | 55111-0647 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | June 28, 2010 | In Use | ||
55111-0646-79 | 55111-0646 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | June 3, 2011 | In Use | ||
55111-0646-78 | 55111-0646 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | June 3, 2011 | In Use | ||
55111-0646-30 | 55111-0646 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | June 3, 2011 | In Use | ||
55111-0556-10 | 55111-0556 | Decitabine | Decitabine | 50.0 mg/10mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | July 11, 2013 | In Use | |
55111-0554-90 | 55111-0554 | Finasteride | Finasteride | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | June 19, 2006 | July 31, 2011 | No Longer Used | |
55111-0554-30 | 55111-0554 | Finasteride | Finasteride | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | June 19, 2006 | July 31, 2011 | No Longer Used | |
55111-0497-05 | 55111-0497 | capecitabine | capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Dec. 10, 2020 | In Use | |
55111-0497-04 | 55111-0497 | capecitabine | capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Dec. 10, 2020 | In Use | |
55111-0496-60 | 55111-0496 | capecitabine | capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Dec. 10, 2020 | In Use | |
55111-0496-05 | 55111-0496 | capecitabine | capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Dec. 10, 2020 | In Use | |
55111-0172-90 | 55111-0172 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb. 28, 2007 | In Use | |
55111-0172-79 | 55111-0172 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb. 28, 2007 | In Use | |
55111-0172-78 | 55111-0172 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb. 28, 2007 | In Use | |
55111-0172-30 | 55111-0172 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb. 28, 2007 | In Use | |
55111-0172-05 | 55111-0172 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb. 28, 2007 | In Use | |
55111-0172-01 | 55111-0172 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb. 28, 2007 | In Use | |
55111-0156-78 | 55111-0156 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 24.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec. 26, 2006 | In Use | |
55111-0156-30 | 55111-0156 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 24.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec. 26, 2006 | In Use | |
55111-0156-11 | 55111-0156 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 24.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec. 26, 2006 | In Use | |
55111-0156-05 | 55111-0156 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 24.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec. 26, 2006 | In Use | |
55111-0154-78 | 55111-0154 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec. 26, 2006 | In Use |
Found 10,000 results in 11 milliseconds — Export these results